Stay updated with breaking news from Stabilized Injectable Formulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020...
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The
Multicenter, multinational Phase 3 Casppian study will evaluate the efficacy, safety, and pharmacokinetics of leuprolide (FP-001) 42 mg-controlled release in...
TAIPEI, Taiwan, Sept. 30, 2023 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") announced today that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia
TAIPEI, May 31, 2022 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the European Commission (EC) has approved the Marketing Authorization Application (MAA)